Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
Charalampos Tzanetakos1*, Andreas Melidonis2, Christos Verras2, Georgia Kourlaba3 and Nikos Maniadakis1
Study protocol of EMPOWER Participatory Action Research (EMPOWER-PAR): a pragmatic cluster randomised controlled trial of multifaceted chronic disease management strategies to improve diabetes and hypertension outcomes
in primary care
Anis S Ramli1*, Sharmila Lakshmanan2, Jamaiyah Haniff2, Sharmini Selvarajah3, Seng F Tong4, Mohamad-Adam Bujang2, Suraya Abdul-Razak1, Asrul A Shafie5, Verna KM Lee6, Thuhairah H Abdul-Rahman7, Maryam H Daud1, Kien K Ng1, Farnaza Ariffin1, Hasidah Abdul-Hamid1, Md-Yasin Mazapuspavina1, Nafiza Mat-Nasir1, Maizatullifah Miskan1,
Jaya P Stanley-Ponniah2, Mastura Ismail8, Chun W Chan6, Yong R Abdul-Rahman9, Boon-How Chew10
The protein-sparing modified fast for obese patients with type 2 diabetes: What to expect
JULIA CHANG, BS, MSIII
Case Western Reserve University School of Medicine, Cleveland, OH
SANGEETA R. KASHYAP, MD*
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic; Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
In−Hospital Mortality Among Patients With Type 2 Diabetes Mellitus and Acute Myocardial Infarction: Results From the National Inpatient Sample, 2000−2010
Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure
Ewa A. Jankowska1,2*, Monika Kasztura3, Mateusz Sokolski2,4, Marek Bronisz5, Sylwia Nawrocka2, Weronika Oles ́kowska-Florek5, Robert Zymlin ́ ski2, Jan Biegus2, Paweł Siwołowski2, Waldemar Banasiak2, Stefan D. Anker6,7, Gerasimos Filippatos8, John G.F. Cleland9, and Piotr Ponikowski2,4
Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial
Uwe Zeymer1*, Arnoud van ’t Hof2, Jennifer Adgey3, Lutz Nibbe4, Peter Clemmensen5, Claudio Cavallini6, Jurrien ten Berg7, Pierre Coste8, Kurt Huber9,
Efthymios N. Deliargyris10, Jonathan Day10, Debra Bernstein10, Patrick Goldstein11, Christian Hamm12, and Philippe Gabriel Steg13,14,15
